Advertisement


Christopher J. Sweeney, MBBS, on Prostate Cancer: CHAARTED Trial Follow-up

2016 ESMO Congress

Advertisement

Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how long-term study results showed no survival benefit in men with ogliometastatic prostate cancer. (Abstract 720PD)



Related Videos

Lung Cancer

Fabrice Barlesi, MD, PhD, on NSCLC: Results From the OAK Trial (French Language Version)

Fabrice Barlesi, MD, PhD, of Aix Marseille University and Assistance Publique Hopitaux De Marseille, discusses in French phase III findings on a comparison of atezolizumab with doceta...

Lung Cancer

Fabrice Barlesi, MD, PhD, on NSCLC: Results From the OAK Trial

Fabrice Barlesi, MD, PhD, of Aix Marseille University and Assistance Publique Hopitaux De Marseille, discusses phase III findings on a comparison of atezolizumab with docetaxel in pat...

Prostate Cancer

Christopher J. Sweeney, MBBS, on Localized Prostate Cancer: Metastasis-Free Survival as a Surrogate for Overall Survival

Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how this early clinical endpoint will accelerate the development of new therapies for localized intermedia...

Breast Cancer

Sara A. Hurvitz, MD, on Breast Cancer: Results From the neoMONARCH Trial

Sara A. Hurvitz, MD, of the University of California, Los Angeles, discusses interim findings on abemaciclib in postmenopausal women with HR+/HER2- breast cancer. (Abstract LBA13)

Kidney Cancer

Toni K. Choueiri, MD, on Metastatic RCC: Results From the ALLIANCE A031203 Trial

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses study findings on cabozantinib vs sunitinib as initial targeted therapy for patients with metastatic renal cell ca...

Advertisement

Advertisement



Advertisement